Antibody Bacteria Biobanking Protein 
Drug Discovery World
OCTOBER 13, 2022
There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. . Looking forward .
The Pharma Data
JANUARY 21, 2021
Doctors need better tools to evaluate the status of COVID-19 patients as early as possible because many of the treatments—such as monoclonal antibodies—are in short supply, and we know that some patients will get better without intensive treatments,” said co-senior author Andrew E. The research was published in the journal JCI Insight.
Expert insights. Personalized for you.
52 
Let's personalize your content